The Net Margin of Rhythm Pharmaceuticals, Inc. (RYTM) is
-103.57%.
Net Margin measures the percentage of net income derived from total revenue after all expenses. It signals how much actual profit a company retains from its sales.
| Date |
Value |
| 2025-12-31 |
-103.57%
|
| 2024-12-31 |
-200.27%
|
| 2023-12-31 |
-238.52%
|
| 2022-12-31 |
-766.16%
|
| 2021-12-31 |
-2209.84%
|
| Ticker |
Name |
Value |
|
KNSA
|
Kiniksa Pharmaceuticals International, PLC
|
8.71%
|
|
REGN
|
Regeneron Pharmaceuticals, Inc.
|
31.41%
|
|
YMAB
|
Y-mAbs Therapeutics Inc
|
-33.83%
|
|
AMGN
|
Amgen Inc
|
20.98%
|
|
SNDX
|
Syndax Pharmaceuticals, Inc.
|
-165.60%
|
|
MRSN
|
Mersana Therapeutics Inc
|
-170.86%
|
|
950160.KQ
|
Kolon TissueGene Inc
|
-3733.25%
|
|
PRAX
|
Praxis Precision Medicines, Inc.
|
-2137.48%
|
|
950220.KQ
|
Neoimmunetech Inc
|
-33533.01%
|
|
ATRA
|
Atara Biotherapeutics, Inc.
|
27.07%
|
|
CYDY
|
Cytodyn Inc
|
-79255.64%
|
|
ITOS
|
iTeos Therapeutics Inc
|
-384.04%
|
|
MRNA
|
Moderna, Inc.
|
-145.16%
|
|
PRTA
|
Prothena Corporation PLC
|
-2520.57%
|
|
AFMD
|
Affimed NV
|
-1280.22%
|
|
ARCT
|
Arcturus Therapeutics Holdings Inc
|
-80.19%
|
|
NWBO
|
Northwest Biotherapeutics Inc
|
-4365.89%
|
|
TRIL.TO
|
Trillium Therapeutics Inc
|
-39566.70%
|
|
BTAI
|
BioXcel Therapeutics Inc
|
-10887.38%
|
|
GILD
|
Gilead Sciences, Inc.
|
28.90%
|
|
DVAX
|
Dynavax Technologies Corp
|
9.85%
|
|
FDMT
|
4D Molecular Therapeutics Inc
|
-164.43%
|
|
STOK
|
Stoke Therapeutics, Inc.
|
-3.73%
|
|
TSHA
|
Taysha Gene Therapies, Inc.
|
-1115.27%
|
|
VRTX
|
Vertex Pharmaceuticals Incorporated
|
32.94%
|
|
950200.KQ
|
Psomagen Inc
|
-5.04%
|
|
ABBV
|
AbbVie Inc.
|
6.91%
|
|
KROS
|
Keros Therapeutics, Inc.
|
35.65%
|